miR-155 is considered as an oncomiR with implications in pathogenesis of AML (O’Connell et al., 2008; Palma et al., 2014); it has been associated with SHIP1 (negatively regulator of PI3K/AKT pathway) and CEBP-β (Gorgoni et al., 2002; O’Connell et al., 2009). This evidence concerns the gene CEBPB and acute myeloid leukemia.